This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 17.74% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Marinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in Session
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
Implied Volatility Surging for Marinus (MRNS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) shares rose nearly 8% in the last trading session, amid huge volumes.
Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
by Zacks Equity Research
Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.
Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings
by Zacks Equity Research
Oracle (ORCL) is benefiting from increasing adoption of its product portfolio and synergies from strategic buyouts.
Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Broadcom (AVGO) extensive product portfolio is likely to positively impact the to-be-reported quarter's results.
Options Traders Expect Huge Moves in Marinus Pharmaceuticals (MRNS) Stock
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) needs investors to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
Marinus Stock Surges on Successful Phase II Epilepsy Study
by Zacks Equity Research
Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.
Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US
by Zacks Equity Research
Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.
Marinus Releases Positive Preliminary Data from CDKL5 Study
by Zacks Equity Research
Marinus Pharmaceuticals, Inc. (MRNS), announced positive preliminary data from the initial CDKL5 pediatric patients enrolled in its ongoing phase II study assessing pipeline candidate, ganaxolone, for the treatment of orphan, genetic disorders.